(P035) The Prognostic Value of Pretreatment Peripheral Blood Neutrophil-to-Lymphocyte Ratio in Patients With Soft Tissue Sarcoma

Publication
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

While our results do not demonstrate high neutrophil-to-lymphocyte ratio to be an independent risk factor for worsened clinical outcomes, they do show high neutrophil-to-lymphocyte ratio to have statistically and clinically significant predictive value for RFS and OS in patients with recently diagnosed soft tissue sarcoma.

William H. Smith, Vishal Gupta, MD, Elizabeth G. Demicco, MD, Ilya Iofin, MD, Robert G. Maki, MD, PhD; Icahn School of Medicine at Mount Sinai

PURPOSES/OBJECTIVES: There has been growing interest in the prognostic value of peripheral blood neutrophil-to-lymphocyte ratio (NLR) in solid malignancies, but there are limited data on sarcomas. In this study, we sought to elucidate the relationship between pretreatment NLR and relapse-free survival (RFS) and overall survival (OS) in patients with recently diagnosed soft tissue sarcoma (STS).

METHODS: We queried our institutional pathology database for patients diagnosed with STS between January 2009 and December 2013. Included patients had pretreatment peripheral blood complete blood count (CBC) available within 1 month of surgery and prior to chemotherapy/radiation therapy (RT). Patients with rhabdomyosarcoma and solitary fibrous tumor histology were excluded. Patients were categorized into high- NLR (NLR ≥ 5) and low-NLR (NLR  < 5) groups based on CBC. Clinical patient data were obtained, and OS and RFS were compared using Kaplan-Meier analysis and Cox proportional hazards analysis.

RESULTS: A total of 122 patients met the inclusion criteria for our study. Among these patients, 26 (21%) were included in the high-NLR group, and 88 (72%) formed the low-NLR group. Eight (7%) had CBC without differential and were included solely for multivariate analysis. After a median follow-up of 19 months, high pretreatment NLR was associated with increased risk of mortality (hazard ratio [HR], 2.499 [95% CI, 1.193–5.232]) and increased risk of recurrence (HR, 2.688 [95% CI, 1.093–6.611]). On multivariate analysis with Cox proportional hazards modeling, this effect was not found to be significant after correction for age, stage, and histologic subtype.

DISCUSSION: While our results do not demonstrate high NLR to be an independent risk factor for worsened clinical outcomes, they do show high NLR to have statistically and clinically significant predictive value for RFS and OS in patients with recently diagnosed STS. Longer follow-up and more patients are needed to validate these findings.

Proceedings of the 98th Annual Meeting of the American Radium Society -americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer
Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Related Content